Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?

How many big biotech acquisitions can you name that have occurred so far in 2017?

Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well, actually, that's it. J&J's acquisition of Actelion is the only truly big biotech buyout year to date, unless you also want to include Japanese drugmaker Takeda's $5.2 billion deal to buy Ariad in the first quarter.

Why has 2017 been such a horrible year so far for biotech acquisitions? Here's the answer -- and why next year could see a flood of deals.

Source: Fool.com